PAPER

Biodegradable hyperbranched polyether-lipids with in-chain pH-sensitive linkages

S. S. Müller,[a,b] T. Fritz,[c] M. Gimnich,[a] M. Worm,[a] M. Helm[c] and H. Frey*[a]

Hyperbranched polyether-based lipids with cleavable acetal units were obtained *via* copolymerization of the epoxide inimer 1-(glycidyloxy)ethyl ethylene glycol ether (GEGE) and glycidol, using anionic ring-opening polymerization. Cholesterol-linear polyglycerol (Ch-*lin*PG) was used as a macroinitiator, resulting in branched polyethers with an adjustable amount of acid-cleavable units. Random copolymerization led to Ch-P(GEGE$_x$-*co*-G$_y$) copolymers, whereas sequential copolymerization provided access to Ch-P(GEGE$_x$-*b*-G$_y$) amphiphiles. The amount of GEGE was varied between 8–49 mol% of the total amount of monomer units. In addition, hyperbranched polyethers with a single acetal unit were prepared using glycol-1-(cholesteryloxy)ethylether as an initiator for the polymerization of allyl glycidyl ether (AGE) in bulk. Subsequent thiol–ene coupling of mercaptoethanol resulted in the hydroxyl functional macroinitiator used for the polymerization of glycidol. The novel polyether-based lipids were characterized in detail by ^{1}H NMR spectroscopy and size exclusion chromatography, revealing narrow to moderate molecular weight distributions. Degradation was achieved at pH 2 in a proof-of-principle experiment. Acid-triggered shedding of liposomes was proven using the linear analogue α-(1-(cholesteryloxy)ethoxy)-ω-hydro-PEG-CH$_2$-C≡CH with one cleavable group and a fluorescence label, Atto 488 azide. Investigation of the acetal-cleavage under neutral and acidic pH (7.4–2.0) *via* fluorescence spectroscopy was carried out.

Introduction

Drug delivery vehicles, such as liposomes, are well known carriers, especially in anti-cancer treatment.[1,2] Liposomes consist of amphiphilic phospholipids that form spherical vesicles in aqueous solution. Effective delivery systems enable an important step towards minimizing undesired effects of extremely toxic drugs, such as doxorubicin, on healthy tissue. Disadvantages like cardiotoxicity of doxorubicin and short circulation times can be avoided. The use of poly(ethylene glycol) (PEG) as a polymer shell at the liposome surface has become a popular approach to create long-circulating liposomes.[3,4] These systems are also called sterically stabilized or "stealth" liposomes, since the PEGylated liposomes obtain extraordinary properties due to the water-soluble and flexible polymer chains. The presence of PEG results in prolonged blood circulation times,[5,6] reduced mononuclear phagocyte system (MPS) uptake,[7] reduced aggregation of the carriers and increasing colloidal stability.[8] Nevertheless, the gold standard PEG pos-

sesses drawbacks that need to be overcome in advanced drug delivery systems. Having reached the target tissue and cells, the PEG shell can prevent the liposome from penetrating into cells or escaping from the endosome after endocytosis (PEG dilemma).[9,10] Currently established drug delivery systems that are based on such liposomes fail to release the drug actively and rely on passive diffusion or slow and non-specific liposome degradation. Ideally, PEGylated liposomes profit from the enhanced permeability and retention (EPR) effect,[11] and are stable under physiological pH (pH 7.4). Preferentially, the polymer coating would be detached under local pathological conditions such as low pH, leading to destabilization and release of the cargo. The slightly acidic environment in endosomes, tumor tissues, or inflammatory tissue is one of the main differences to healthy tissue. Endocytic pathways lead to a drop from a neutral pH to pH 6 in late endosomes and pH 4 in lysosomes.[12,13] Cancer and inflammatory tissue also exhibit acidic pH around pH 6.5.[14] A perfectly tuned pH-sensitive nanoparticle would shed the polymer coating and thus enable membrane–membrane fusion and internalization. Fusion with the endosomal membrane is especially important for the release of a cargo into the cytoplasm.[15,16] This escape is crucial for acid-degradable cargo such as small interfering RNA (siRNA), proteins or acid-labile drugs.[17] The need for "stealth" liposomes that are stable under physiological conditions, but release their content at decreased pH at the site of

[a]*Institute of Organic Chemistry, Johannes Gutenberg University Mainz, Duesbergweg 10-14, 55128 Mainz, Germany. E-mail: hfrey@uni-mainz.de*
[b]*Graduate School Materials Science in Mainz (MAINZ), Staudingerweg 9, 55128 Mainz, Germany*
[c]*Institute of Pharmacy and Biochemistry, Johannes Gutenberg University Mainz, Staudingerweg 5, 55128 Mainz, Germany*

action is proposed in an increasing number of publications in this field. Several examples have been reported for controlled release including acetals,[18,19] vinyl ethers,[20–22] (di-)*ortho* esters,[23–25] hydrazones,[26–28] and esters (*e.g.* succinates).[29,30] The second drawback of PEG is its lack of functional groups. Methoxypoly(ethylene glycol) (mPEG), that is commonly used for the linkage to phospholipids or cholesterol, does not possess additional functional groups for derivatization. However, functional groups are important for the attachment of markers, antibodies or proteins for "active" tumor targeting.[31] Our group has introduced multifunctional polyether-based lipids synthesized from an epoxide "construction kit".[32–34] By using cholesterol directly as the initiator for the oxyanionic ring-opening polymerization (ROP) of various epoxides (ethylene oxide (EO), ethoxyethyl glycidyl ether (EEGE), isopropylidene glycidyl glyceryl ether (IGG), and glycidol), a variety of tailor-made architectures like linear, hyperbranched or linear-hyperbranched polyether amphiphiles can be obtained. The hyperbranched structures can be realized by using glycidol in the ring-opening multibranching polymerization technique *via* slow monomer addition (SMA) of the AB$_2$ monomer to a multihydroxy-precursor. With this method reproducible and narrowly distributed hyperbranched polyglycerol (*hb*PG) derivatives can be obtained.[35] Furthermore, the number of hydroxyl groups can be accurately tuned by the amount of glycidol utilized. *Hb*PG has been extensively studied in drug delivery applications and as a biorepellent material due to its extraordinary biocompatibility,[36–38] multifunctionality and water-solubility.[39] Similar to the abovementioned PEG-lipids, its non-biodegradability can be an issue in special applications. To overcome this drawback, pH-sensitive polyether polyketals with tunable degradation in solution were synthesized by Kizhakkedathu and coworkers.[40–42]

Hyperbranched acetal-containing polyethers were introduced by our group using the epoxide inimer 1-(glycidyloxy)ethyl ethylene glycol ether (GEGE) in a copolymerization reaction with glycidol.[43]

In the present study, we combine the benefits of multifunctional polyether-based lipids with the degradability of pH-sensitive acetal-containing polyglycerol. In all cases, cholesterol moieties were employed as the hydrophobic part of the amphiphilic structure, ensuring strong interaction with the phospholipid bilayer of liposomes. In the first strategy, we show the synthesis of hyperbranched acetal-containing polyglycerol using GEGE and glycidol in a random copolymerization or a sequential polymerization (Fig. 1a and Scheme 1). In the second approach, we expand the concept of glycol-1-(cholesteryloxy)ethylether recently presented by our group.[18] This initiator is used for the polymerization of AGE, and subsequent thiol–ene coupling with 2-mercaptoethanol followed by the polymerization of glycidol. This pathway results in either linear multihydroxy-functional polyethers or hyperbranched polyethers having exactly one acetal group between the cholesterol anchor and the polymer chain (Fig. 1b and Scheme 2). In the third case, the scope of α-(1-(cholesteryloxy)ethoxy)-ω-hydro-PEG is extended by the functionalization with propargyl bromide followed by copper-catalyzed cycloaddition with Atto 488 azide. Acidic cleavage of the acetal group in functionalized liposomes was investigated *via* fluorescence spectroscopy. The shedding process could be monitored by fluorescence emission of the dye Atto 488 (Fig. 1c and 8).

With these different polymer systems comprising multiple or single acetal groups in hand, we introduce a platform of lipids that combine desired lipid pH-responsiveness with multifunctionality for drug delivery applications.


Fig. 1 Synthesis of (a) hyperbranched polyglycerol lipids containing multiple acetal groups by using GEGE and glycidol in a random copolymerization or a sequential polymerization (b) hyperbranched polyether lipids with exactly one acetal group at the block junctions utilizing glycol-1-(cholesteryloxy)ethylether as an initiator (c) linear PEG lipids with one cleavable group functionalized with the fluorescent dye Atto 448.

Scheme 1 Reaction scheme for the synthesis of the macroinitiator Ch-*lin*PG$_n$, followed by the slow monomer addition of GEGE and glycidol, which can be carried out simultaneously or sequentially as depicted here.

Scheme 2 Synthesis of hyperbranched cholesterol-lipids with exactly one acetal group starting from glycol-1-(cholesteryloxy)ethylether (Ch-acetal); (SMA = slow monomer addition).

Experimental

Methods

^{1}H NMR spectra (300 MHz and 400 MHz) were recorded using a Bruker AC300 or a Bruker AMX400, employing CD$_2$Cl$_2$, MeOD, or THF-d_8 as solvent. All spectra were referenced internally to residual proton signals of the deuterated solvent. Size exclusion chromatography (SEC) measurements were carried out in dimethylformamide (DMF) with 0.25 g L^{-1} LiBr on PSS

HEMA columns (300/100/40). For SEC measurements UV (275 nm) and RI detectors were used. Calibration was carried out using poly(ethylene glycol) (PEG) standards provided by Polymer Standards Service (PSS). Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-ToF MS) measurements were performed on a Shimadzu Axima CFR MALDI-ToF mass spectrometer equipped with a nitrogen laser delivering 3 ns laser pulses at 337 nm. Dithranol was used as a matrix. The sample was prepared by dissolving the polymer in

methanol at a concentration of 10 g L^{-1}. A 10 μL aliquot of this solution was added to 10 μL of a 10 g L^{-1} solution of the matrix and 1 μL of a solution of potassium trifluoroacetate (KTFA) (0.1 M in methanol as a cationization agent). A 1 μL aliquot of the mixture was applied to a multistage target, methanol evaporated and a thin matrix/analyte film created.

Liposome preparation

Liposomes bearing acetal-containing cholesterol-based amphiphiles were prepared as described previously.[44,45] Briefly, 32.5 μl of phosphate buffered saline (PBS) (137 mM NaCl, 2.7 mM KCl, 10 mM Na$_2$HPO$_4$, 2 mM KH$_2$PO$_4$, pH 7.4) was added to 17.5 mg of a dried lipid film consisting of cholesterol (Carl Roth), egg phosphatidyl choline (EPC, kindly provided by Lipoid) and α-(1-cholesteryloxy)ethoxy)-ω-Hydro-PEG$_{46}$-CH$_2$-C≡CH (40 : 55 : 5 molar ratio) and 250 mg ceramic beads (SiLiBeads ZY 0.6–0.8 mm, kindly provided by Sigmund Lindner, Warmensteinach, Germany). Non-cleavable liposomes were prepared with an equivalent cholesterol-PEG-CH$_2$-C≡CH compound. After dual centrifugation in a Rotanta 400 centrifuge (customized with a prototype DC-rotor, Hettich, Tuttlingen, Germany) for 20 min at 2500 RPM and dilution with 100 μl PBS, 5 μl of the liposome suspension were exposed to click-modification with 50 μM Atto 488 azide (Atto-Tec, Siegen, Germany) in Milli-Q water (to a total volume of 40 μl), phosphate buffer (5.3 mM NaH$_2$PO$_4$, 94.7 mM Na$_2$HPO$_4$, pH 8), Tris(hydroxypropyltriazolylmethyl)amine (THPTA) (0.5 mM), CuSO$_4$ (0.1 mM) and sodium ascorbate (2.5 mM) and subsequent gel filtration through Sepharose 2B. Liposome size was obtained *via* dynamic light scattering (DLS) on a Malvern Zetasizer Nano ZS, using disposable poly(styrene) cuvettes (Sarstedt, Germany). 1 μl of liposome stock suspension was diluted in 1 ml PBS. After equilibration to 25 °C, three measurements were performed, using the internal measurement optimization for both attenuator and measurement position. Refractive index (RI) and viscosity of the dispersant was set to 1.330 and 0.8872 cP, the RI of the particle to 1.59. The absorption of the particle was set to 0.01 and all measurements were performed at a scattering angle of 173°. Cleavage of the polymeric liposome shell was observed *via* fluorescence spectroscopy on a FP-6500 spectrofluorimeter (Jasco, Tokyo, Japan) at 488 nm excitation wavelength and 523 nm emission wavelength during a time course measurement with a data interval of 1 min. 50 μl of purified liposomes were combined with 3 ml PBS in a 1 cm^3 quartz glass cuvette (Hellma Analytics, Müllheim, Germany) with a magnetic stirrer. After equilibration for 12 h at 37 °C, the pH of the suspension was adjusted by addition of 50 μl 2 M hydrochloric acid (HCl) (pH 2), 20 μl 2 M HCl (pH 3) or 15 μl 2 M HCl (pH 5.5). Fluorescence intensity was normalized to the intensity at the beginning of acidification.

Syntheses and reagents

All reagents and solvents were purchased from Acros and used as received, unless otherwise mentioned. Anhydrous solvents were stored over molecular sieves and were purchased from Aldrich. Deuterated solvents were purchased from Deutero GmbH, and stored over molecular sieves. Cholesterol was purchased from Acros and stored at 8 °C. Ethoxyethyl glycidyl ether (EEGE) was synthesized as described in the literature,[46] dried over CaH$_2$ and cryo-transferred prior to use. Glycidol and *N*-methyl-2-pyrrolidon (NMP) were purified by distillation from CaH$_2$ directly prior to use. 1-(Glycidyloxy)ethyl ethylene glycol ether (GEGE) was synthesized according to the literature.[43] To release the hydroxyl group in the final reaction step, the benzyl protecting group was removed using catalytic hydrogenation (Pd(OH)$_2$/C, 10 wt%). The product was purified by column chromatography in ethyl acetate. Glycol-1-(cholesteryloxy)ethylether and α-(1-(cholesteryloxy)ethoxy)-ω-Hydro-PEG$_{46}$ were synthesized following reported procedures.[18] Propargyl bromide (0.8 M in toluene) was stored at 4 °C and used as received. Allyl glycidyl ether (AGE) was purchased from Acros Organics, dried over CaH$_2$ and cryo-transferred prior to use. Azobisisobutyronitrile (AIBN, Acros) was recrystallized from MeOH. 2-Mercaptoethanol (Acros) was stored at 5 °C and was used as received.

Macroinitiator: cholesterol initiated linear poly(glycerol) (Ch-*lin*PG$_{20}$; Ch-*lin*PG$_{13}$). Cholesterol (2.0 g, 5.2 mmol), CsOH monohydrate (0.782 g, 4.7 mmol, 90% of deprotonation), and benzene (8 mL) were placed in a Schlenk flask. The mixture was stirred at 60 °C for about 30 min to generate the cesium alkoxide. The salt was then dried under vacuum at 90 °C for 24 h. The salt was suspended in 60 mL anhydrous dioxane, the monomer EEGE was added (5.5 mL, 36 mmol, 7 eq.) and the mixture was heated up to 80 °C for 24 h. A sample was removed for NMR and SEC analysis, the polymerization was stopped *via* addition of an excess of methanol and the acetal protecting groups of PEEGE were cleaved by the addition of an acidic ion-exchange resin (Dowex 50WX8) and 2 N HCl, stirring at 40 °C for 24 h. The solution was filtered, concentrated, and the crude product was precipitated twice in cold diethyl ether. The block copolymer was dried under vacuum. Yield: ~80%. No ^{1}H NMR spectrum was measured before the deprotection step, because residual cholesterol was detected in SEC diagrams, leading to incorrect integration of the resonances. ^{1}H NMR (300 MHz, MeOD-d_4): δ (ppm) = 5.37 (C=C*H* cholesterol), 3.80–3.40 (polyether backbone; C*H*O cholesterol), 2.40–0.82 (C*H*$_2$, C*H* cholesterol), 0.72 (–C*H*$_3$ cholesterol).

Ch-Poly(1-(glycidyloxy)ethyl ethylene glycol ether-*co*-glycerol) Ch-P(GEGE$_x$-*co*-G$_y$). For random copolymerization of GEGE and glycidol Ch-*lin*PG$_{20}$ was used, and for sequential copolymerization (block copolymers) Ch-*lin*PG$_{13}$ was used as the macroinitiator. General procedure for the copolymerization of glycidol and GEGE: Ch-*lin*PG$_{13}$ (0.20 g, 0.15 mmol), CsOH monohydrate (10% of OH groups, 0.035 g, 0.21 mmol), and 1.2 mL of benzene were placed in a Schlenk flask and stirred at 60 °C for 30 min. All solvents were removed under reduced pressure, and the initiator salt was dried at 90 °C for at least 4 h under high vacuum. The initiator salt was dissolved in NMP and a mixture of glycidol in NMP and GEGE in NMP was slowly added under argon atmosphere using a syringe pump. For random copolymerization the monomers were mixed in

NMP and slowly added, whereas for block copolymers, GEGE in NMP was added before glycidol in NMP was added. The reaction was terminated by the addition of an excess of methanol. The mixture was concentrated and precipitated (2–4 times) into an excess of cold diethyl ether. Yield: 60–75%. ^{1}H NMR (300 MHz, MeOD-d_4): δ (ppm) = 5.38 (C=CH cholesterol), 4.79 (H_3C–CHO$_2$, GEGE acetal group), 3.80–3.40 (polyether backbone; CHO cholesterol), 2.36–0.87 (CH_2, CH cholesterol), 1.32 (H_3C–CHO$_2$, GEGE), 0.72 (–CH_3 cholesterol).

α-(1-(Cholesteryloxy)ethoxy)-ω-hydro-poly(allyl glycidyl ether) in bulk. Glycol-1-(cholesteryloxy)ethylether (0.3 g, 0.63 mmol), CsOH monohydrate (0.095 g, 0.57 mmol; degree of deprotonation 90%), and benzene (8 mL) were placed in a Schlenk flask. The mixture was stirred for about 30 min at 60 °C to generate the cesium alkoxide. The salt was then dried under vacuum at 90 °C for 3 h. The monomer AGE was added (1.45 mL, 12.6 mmol, 20 eq.) and the mixture was heated up to 65 °C for 24 h. The polymerization was stopped using an excess of methanol. Yield: ~98%. Ch-OCHCH$_3$O-PAGE$_{20}$: ^{1}H NMR (300 MHz, CD$_2$Cl$_2$): δ (ppm) = 5.93 (–CH$_2$CH=CH$_2$, allyl), 5.39 (C=CH cholesterol), 5.33–5.17 (–CH$_2$CH=CH_2, allyl), 4.82 (H_3C–CHO$_2$, acetal group), 4.01 (–CH_2CH=CH$_2$), 3.80–3.39 (polyether backbone; CHO cholesterol), 2.32–0.88 (CH_2, CH cholesterol), 1.30 (H_3C–CHO$_2$), 0.72 (–CH_3 cholesterol).

Thiol–ene coupling of Ch-OCHCH$_3$O-PAGE$_{20}$ with 2-mercaptoethanol. Ch-OCHCH$_3$O-PAGE$_{20}$ (0.3 g, 0.1 mmol), 270 mg AIBN (0.75 eq. for each allyl group), and 2-mercaptoethanol (1.55 mL, 22 mmol, 10 eq. of allyl groups) were dissolved in 10 mL DMF. After three freeze–pump–thaw cycles, the mixture was stirred at 75 °C for 24 h. For purification, the reaction mixture was dialyzed against MeOH (MWCO = 1000 g mol^{-1}) for two days and dried under vacuum to give the polymer with a sticky appearance. Yield: 83%. ^{1}H NMR (400 MHz, THF-d_8): δ (ppm) = 5.34 (C=CH cholesterol), 4.81 (H_3C–CHO$_2$, acetal group), 4.00–3.30 (polyether backbone; CHO cholesterol), 2.72–2.40 (–CH_2SCH_2), 1.83 (–CH$_2$CH_2S), 2.37–0.87 (CH_2, CH cholesterol), 0.72 (–CH_3 cholesterol).

Hypergrafting of glycidol onto Ch-OCHCH$_3$O–thiol-coupling$_{20}$. The macroinitiator Ch-OCHCH$_3$O–thiol-coupling$_{20}$ (0.2 g, 0.05 mmol), CsOH monohydrate (20% of OH groups, 0.033 g, 0.19 mmol), and benzene were placed in a Schlenk flask and stirred at 60 °C for 30 min. All solvents were removed under reduced pressure and the initiator salt was dried at 90 °C for 24 h under vacuum. The initiator salt was dissolved in 0.5 mL NMP and glycidol in NMP (0.5 mL, 20 wt%) was slowly added under argon atmosphere using a syringe pump. The reaction was terminated by the addition of excess of methanol. The mixture was concentrated and precipitated into an excess of cold diethyl ether. Residual NMP could be removed by drying under vacuum and washing with CH$_2$Cl$_2$. Yield: 80%.

^{1}H NMR (400 MHz, DMSO-d_6): δ (ppm) = 5.32 (C=CH cholesterol), 5.11 (–OH) 4.81 (H_3C–CHO$_2$, acetal group), 3.90–3.20 (polyether backbone; CHO cholesterol), 2.65–2.52 (–CH_2SCH_2), 1.74 (–CH$_2$CH_2S), 2.40–0.84 (CH_2, CH cholesterol), 0.65 (–CH_3 cholesterol).

Etherification of α-(1-(cholesteryloxy)ethoxy)-ω-hydro-PEG$_{46}$ with propargyl bromide. α-(1-(Cholesteryloxy)ethoxy)-ω-Hydro-PEG$_{46}$ (0.4 g, 0.16 mmol) was dissolved in anhydrous THF (7 mL), and sodium hydride (9.6 mg, 0.4 mmol) was slowly added under an argon stream at 0 °C. The reaction mixture was stirred for 30 min and after slow addition of propargyl bromide (0.17 mL, 0.6 mmol) allowed to warm up to room temperature. The reaction was stirred at room temperature for 24 h and was filtered. Removal of the solvent *in vacuo* and precipitation in cold diethyl ether resulted in the pure product. Yield: 90%. ^{1}H NMR (400 MHz, CD$_2$Cl$_2$): δ (ppm) = 5.34 (C=CH cholesterol), 4.79 (H_3C–CHO$_2$, acetal group), 4.18 (–OCH_2–C≡CH), 3.80–3.40 (polyether backbone; CHO cholesterol), 2.49 (–C≡CH), 2.27–0.82 (CH_2, CH cholesterol), 0.68 (–CH_3 cholesterol).

Results and discussion

Synthesis of amphiphilic hyperbranched lipids with multiple acid-cleavable moieties

Hyperbranched polyether-lipids with multiple pH-responsive acetal groups were prepared by the oxyanionic ring-opening polymerization using cholesterol as an initiator. After deprotonation with cesium hydroxide, the alkoxide was used for the polymerization of ethoxyethyl glycidyl ether (EEGE) with subsequent acidic hydrolysis of the EEGE protecting groups (Scheme 1). Molecular weights for the macroinitiators were in the range of 1300 to 1900 g mol^{-1} (Table 1) according to ^{1}H NMR spectroscopy, with an expected underestimation by size exclusion chromatography (SEC). The linear polyglycerol repeating units were calculated by comparing the methyl group of cholesterol (0.72 ppm) and the polyether backbone resonances after acidic cleavage of the acetal protecting groups from the EEGE moieties. Molecular weights calculated by ^{1}H NMR spectroscopy for both macroinitiators were higher than the theoretical values. We aimed at seven glycerol units per macroinitiator, however, 20 and 13 units were obtained,

Table 1 Characterization data of the macroinitiators (Ch-linPG$_{20}$; Ch-linPG$_{13}$) and the pH-responsive copolymers (random: Ch-P(GEGE$_x$-co-G$_y$); block: Ch-P(GEGE$_x$-b-G$_y$))

Composition	M_n^{theo}	M_n^{NMR}	M_n^{SEC}	$Đ^{SEC}$	GEGE mol%
	g mol^{-1}				
Ch-linPG$_{20}$	904	1870	830	1.05	—
Ch-P(GEGE$_4$-co-G$_{48}$)	4160	4600	1600	1.57	8
Ch-P(GEGE$_{20}$-co-G$_{49}$)	5040	7200	2100	1.60	29
Ch-linPG$_{13}$	904	1350	980	1.14	—
Ch-P(GEGE$_{10}$-b-G$_{36}$)	4220	4700	2500	1.24	22
Ch-P(GEGE$_{18}$-b-G$_{36}$)	4660	6000	3000	1.29	33
Ch-P(GEGE$_{17}$-b-G$_{18}$)	4600	4500	2200	1.22	49

M_n^{theo}: theoretical molecular weights; M_n^{NMR}: molecular weights calculated from ^{1}H NMR *via* end group analysis; M_n^{SEC}: molecular weights obtained from size exclusion chromatography using PEG standards for calibration; $Đ^{SEC} = M_w/M_n$: dispersity determined from SEC *via* PEG calibration; GEGE mol%: molar content of GEGE calculated from ^{1}H NMR.

respectively. Fast proton exchange results in the protonated form of cholesterol and deprotonated adducts of initiator and the first monomer unit.[47–49] This leads to different kinetics in the initiation step and the propagation step, since the ethoxylated cholesterol exhibits higher reactivity than the cholesterol alkoxide. Hence, significant amounts of free initiator are found in the reaction mixture when oligomers are targeted.[50] After acidic hydrolysis of the acetal groups, the polymer was precipitated multiple times in cold diethyl ether to remove excess cholesterol. This led to reduced yields and an enhanced concentration of longer polymer chains.

The resulting linear polyglycerol amphiphiles (Ch-linPG$_{20}$; Ch-linPG$_{13}$) functioned as a macroinitiator for the slow monomer addition of 1-(glycidyloxy)ethyl ethylene glycol ether (GEGE) and glycidol. Partial deprotonation and slow monomer addition allows good control over the alkoxide concentration resulting in equal growth of the polymer chain ends. This technique narrows the molecular weight distribution and prevents undesired homopolymerization of the cyclic inimers.[51] Deprotonation of the macroinitiator was adjusted to 10% (relative to the total amount of hydroxyl groups) in order to ensure solubility in N-methyl-2-pyrrolidon (NMP). Both monomers, *i.e.* GEGE and glycidol, can be copolymerized randomly or sequentially. The reaction route is shown in Scheme 1 (*vide supra*). The advantage of a sequential addition of the monomers, in which GEGE is polymerized first, derives from the proximity of the cleavable acetal group to the cholesterol anchor group. Acidic cleavage would lead to scission near the phospholipid bilayer in the final liposomes, which could enhance shedding of the polymer and drug release.

This approach enabled the synthesis of a series of copolymers bearing multiple acetal groups distributed in the hyperbranched polymer or located near the cholesterol anchor (Table 1).

The random copolymers were prepared from a macroinitiator consisting of 20 linear glycerol units, whereas for the sequentially synthesized copolymers the macroinitiator Ch-linPG$_{13}$ was used. Molecular weights of the hyperbranched lipids were approx. 5000 g mol^{-1}, again with an underestimation in SEC due to differences in the hydrodynamic radius compared to the linear PEG polymer used for calibration. On the other hand, we assume a slight overestimation of the molecular weights in ^{1}H NMR spectroscopy, since residual solvent resonances can overlap with the polyether backbone signals. Molecular weight distributions ($Đ = M_{w}/M_{n}$) below 1.15 were found for the two macroinitiators, whereas for the hyperbranched copolymers $Đ$s below 1.60 could be achieved. The last column of Table 1 summarizes the mol% of GEGE, which were successfully tuned between 8 mol% and 49 mol% (in relation to the total amount of monomer units).

Fig. 2 depicts SEC traces for a selection of copolymers that were synthesized from Ch-linPG$_{13}$ (black solid line, Fig. 2). All distributions were monomodal and molecular weights for the Ch-P(GEGE$_{x}$-b-G$_{y}$) copolymers were shifted to lower elution volumes compared to the macroinitiator. Due the underestimation of molecular weights in SEC, absolute molecular


Fig. 2 SEC traces (RI detection; DMF) for selected copolymer samples that were synthesized from Ch-linPG$_{13}$ (black solid line).

weights were calculated from ^{1}H NMR integration ratios of the resonances for the methyl group of cholesterol at 0.72 ppm and the polyether signals between 4.00–3.27 ppm (Fig. 3). The number of GEGE units was calculated by comparing the integration of the initiator signals (–CH$_{3}$; 0.72 ppm) with the acetal resonance at 4.79 ppm (arrow in Fig. 3). The methyl group of the acetal moieties is observed at 1.32 ppm. As an example, Fig. 3 illustrates the ^{1}H NMR spectra of Ch-linPG$_{13}$ (bottom) and Ch-P(GEGE$_{18}$-b-G$_{36}$) (top) in MeOD.

Synthesis of amphiphilic hyperbranched lipids with exactly one acid-cleavable moiety

In a previous publication, we presented the synthesis of glycol-1-(cholesteryloxy)ethylether (Ch-acetal) as a pH-sensitive initiator for the anionic ring-opening polymerization of ethylene oxide.[18] This initiator can be accessed *via* a three-step procedure by, first, synthesizing 2-acetoxyethyl vinyl ether[52] which can then be converted with commercially available cholesterol under acid catalysis to introduce the acetal group. After saponification of the acetate protecting group, the hydroxyl-functional initiator glycol-1-(cholesteryloxy)ethylether was obtained, which can be used in the anionic polymerization of various epoxides. It was also shown that the pH-sensitive lipid can be cleaved under acidic conditions.[18] Therefore, they are applicable in drug delivery systems, especially for tumor targeting, where the acidic pH of the tumor can be exploited in order to shed the polymer from the vesicle. Here, we expand the idea of exactly one acid-cleavable group in lipids from linear to hyperbranched polyethers. Decomposition products are cholesterol (natural membrane component), biocompatible hyperbranched polyglycerol and acetaldehyde. Since usually the polymer has a molecular weight below 6000 g mol^{-1} excretion by the kidney would be feasible after detachment from the hydrophobic anchor.

The abovementioned EEGE monomer contains an acetal protecting group, which is suitable for the oxyanionic ring-opening polymerization, but has to be cleaved under acidic

Fig. 3 ^{1}H NMR spectra of Ch-linPG$_{13}$ (bottom) and Ch-P(GEGE$_{18}$-b-G$_{36}$) (top) in MeOD.

conditions to obtain the linear polyglycerol as a macroinitiator for the hyperbranched structure. This synthetic route is not suitable in combination with the pH-sensitive initiator glycol-1-(cholesteryloxy)ethylether. Therefore, a different method had to be explored. The first monomer used for experiments with this objective was benzyl glycidyl ether. It is a commercially available glycidyl derivative and can be deprotected under catalytic hydrogenation. Removal of the benzyl groups is usually accomplished with hydrogen pressure in the presence of a palladium catalyst. However, this approach did not lead to successful hydrogenation without cleavage of the acetal group, although different reaction conditions were tested (variation in temperature, pressure, Pd/C $vs.$ Pd(OH)$_2$/C catalyst, solvent mixtures). An altered synthetic route had to be introduced, which is presented in Scheme 2.

After deprotonation with cesium hydroxide, glycol-1-(cholesteryloxy)ethylether was used as an initiator for the oxyanionic ring-opening polymerization of allyl glycidyl ether (AGE). This reaction was carried out in bulk to suppress isomerization of the allyl groups at elevated temperatures.[53,54] Table 2 summarizes the obtained characterization data for Ch-acetal-PAGE and supports quantitative polymerization of AGE. The number of repeating units calculated from ^{1}H NMR spectroscopy (20 AGE groups, see discussion below, Fig. 4) is in agreement with the theoretical number of 20 AGE units. The allyl groups were functionalized in a thiol–ene coupling reaction, using excess 2-mercaptoethanol and azobisisobutyronitrile (AIBN) as the radical initiator. The thiol–ene coupling was quantitative according to ^{1}H NMR spectroscopic characterization. This

Table 2 Characterization data of the allyl containing polyether (Ch-acetal-PAGE$_{20}$), the thioether-functional lipid (Ch-acetal–thiol-coupling$_{20}$.; macroinitiator) and the hyperbranched lipid (Ch-acetal-hbPG$_{35}$) with one single cleavable group

Composition	M_n^{theo}	M_n^{NMR}	M_n^{SEC}	$Đ^{SEC}$
	g mol^{-1}			
Ch-Acetal-PAGE$_{20}$	2750	2750	2050	1.09
Ch-Acetal–thiol-coupling$_{20}$	4320	4320	3430	1.20
Ch-Acetal-hbPG$_{35}$	6500	6900	5000	1.20

M_n^{theo}: theoretical molecular weights; M_n^{NMR}: molecular weights calculated from ^{1}H NMR via end group analysis; M_n^{SEC}: molecular weights obtained from size exclusion chromatography using PEG standards for calibration; $Đ^{SEC} = M_w/M_n$: dispersity determined from SEC via PEG calibration.

amphiphile already represents a novel multihydroxy-functional polyether with exactly one acetal group. Furthermore, it can be used as a macroinitiator for the hypergrafting process of glycidol in order to increase the amount of hydroxyl groups, as shown in Scheme 2. Molecular weights calculated by ^{1}H NMR spectroscopy of the thiolether-containing hyperbranched polymer were around 6500 g mol^{-1}. Table 2 summarizes all characterization data of the abovementioned copolymers. Column 4 illustrates that the molecular weights obtained from SEC (DMF, PEG standard) are lower than the theoretical molecular weights and the molecular weights calculated from ^{1}H NMR spectra. This trend is more pronounced for the hyper-

Fig. 4 SEC traces (RI detection; DMF) for the copolymers with one single acetal group; allyl containing polyether Ch-acetal-PAGE$_{20}$ (black solid line), thiolether-containing lipid Ch-acetal–thiol-coupling$_{20}$ (dashed line), hyperbranched lipid Ch-acetal-hbPG$_{35}$ (dotted line).

branched structure due to the influence of the hyperbranched, globular polyglycerol on the hydrodynamic radius of the polymers compared to linear PEG. Values of $Đ$ were below 1.2 (last column, Table 2). Fig. 4 depicts the SEC traces for all three

polymer species, revealing narrow and monomodal molecular weight distributions.

Molecular weights, degrees of polymerization, and the degree of functionalization with 2-mercaptoethanol were calculated from ^{1}H NMR spectroscopy. The spectra are shown in Fig. 5, in which the allyl functional polymer Ch-acetal-PAGE$_{20}$ (red, top) was measured in CD$_2$Cl$_2$, Ch-acetal–thiol-coupling$_{20}$ (green, middle) was measured in THF-d_8, and Ch-acetal-hbPG$_{35}$ (blue, bottom) was measured in DMSO-d_6. The degree of polymerization for the PAGE copolymer was calculated by comparing the integration of the methyl group of cholesterol (0.72 ppm) with the resonance of the allyl proton at 5.93 ppm. Quantitative conversion was observed, and no isomerization of the allyl groups was found. Between 5.17 and 5.39 ppm an overlap of the allyl group and the cholesterol double bond resonances occurs. The acetal group was retained and its signal was detected at 4.82 ppm. The degree of functionalization for Ch-acetal–thiol-coupling$_{20}$ (green, middle) after thiol–ene coupling was determined by comparing the cholesterol methyl group at 0.72 ppm with the resonances at 1.83 ppm and 2.62 ppm. These two resonances correspond to the methylene groups adjacent to the sulfur (2.62 ppm) and the next but one methylene group. Here, the acetal group at 4.82 ppm and the cholesterol double bond at 5.34 ppm are still intact. After the hypergrafting of glycidol the spectrum for


Fig. 5 ^{1}H NMR spectra for the copolymers with one single acetal group; top to bottom: red: Ch-acetal-PAGE$_{20}$ in CD$_2$Cl$_2$; green: Ch-acetal–thiol-coupling$_{20}$ in THF-d_8; blue: Ch-acetal-hbPG$_{35}$ in DMSO-d_6.

Ch-acetal-hbPG$_{35}$ was obtained in DMSO-d_6 (blue, bottom) which clearly shows that the signals of the methylene groups near the sulfur are still present. The grey frame highlights the acetal resonance, which remains at 4.82 ppm in every stadium of the reaction route. The resonances of the hydroxyl groups appear between 5.00 ppm and 5.20 ppm, whereas the cholesterol double bond shows a peak at 5.32 ppm. The integral of the polyether backbone signals between 3.20 ppm and 3.80 ppm is used to calculate the number of glycidol groups by subtraction of the polyether signals originating from the precursor (macroinitiator). Residual CH_2Cl_2 originates from washing the polymer to remove traces of NMP.

Incorporation of the acetal containing cholesteryl initiator in every polymer chain is crucial for the behavior of the resulting lipid and was verified *via* matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-ToF MS) for Ch-acetal-PAGE$_{20}$ and Ch-acetal–thiol-coupling$_{20}$, as shown in Fig. 6. The use of the lipophilic initiator permits anchoring of the polymers in the liposomal membranes. Fig. 6a shows the distribution of Ch-acetal-PAGE$_{20}$, whereas Fig. 6b depicts the distribution of Ch-acetal–thiol-coupling$_{20}$. In this spectrum, a very small subdistribution was detected, which can be attributed to non-coupled, residual Ch-acetal-PAGE$_{20}$ (marked with an asterisk). An overlap of both spectra is shown in Fig. 6c. The peak differences translate to exactly 114 g mol^{-1}, which represents the molecular weight of the allyl glycidyl ether repeating unit (Fig. 6a). On the other hand, the molecular weight of 192 g mol^{-1}, which corresponds to the hydroxyl functional repeating units ($C_8O_3SH_{16}$), is detectable in the red spectrum in Fig. 6b (Ch-acetal–thiol-coupling$_{20}$). In summary, the MALDI-ToF characterization confirms the structures of the novel lipids.

Degradation of hyperbranched lipid with multiple pH-responsive moieties

The acetal-containing polymer Ch-P(GEGE$_{17}$-b-G$_{18}$) was investigated using SEC measurements with respect to its acidic degradation at room temperature. For this purpose, the sample was dissolved in buffer solution (pH 2) and the sample was stirred for 24 h. Of course, pH 2 is not relevant for the degradation in tumor tissue, but for proof-of-concept studies, acidic hydrolysis can be demonstrated. Fig. 7 depicts the SEC traces of the macroinitiator Ch-linPG$_{13}$ (dotted line), the acetal-containing polymer Ch-P(GEGE$_{17}$-b-G$_{18}$) (black line), and the degraded product of Ch-P(GEGE$_{17}$-b-G$_{18}$) (red line). As expected, the SEC trace for the degraded product shifts to higher elution volume,


Fig. 6 MALDI-ToF spectra for (a) Ch-acetal-PAGE$_{20}$ (b) Ch-acetal–thiol-coupling$_{20}$ (c) overlay of both spectra.

Fig. 7 SEC traces (RI detection; DMF) for the macroinitiator Ch-linPG$_{13}$ (dotted line), the acetal-containing polymer Ch-P(GEGE$_{17}$-b-G$_{18}$) (black line), and the degraded product of Ch-P(GEGE$_{17}$-b-G$_{18}$) (red line).

i.e. lower molecular weights. Furthermore, signals in the lower molecular weight range are observed which can be attributed to "polyether-arms" (fragments) that were cleaved under acidic conditions. The SEC trace for the cleaved polymer does not overlap with the macroinitiator (dotted line). This can be explained by the fact that during the addition of GEGE two different hydroxyl groups are formed. One forms at the end of the acid-labile acetal moiety, and a second one is covalently attached to the macroinitiator. As the likelihood for the addition of the following monomers (GEGE or glycidol) is the same for both hydroxyl groups, only half of the growing arms will be degradable afterwards. Hence, the formation of small fragments and a higher molecular weight mode compared to the macroinitiator, is detected.

pH-Cleavage of Ch-acetal-PEG-CH$_2$-C≡CH and shedding from the liposome

As mentioned above, ideally, a polymer coating should be stable under physiological conditions (pH 7.4), but is cleaved at lower pH, thus enabling membrane–membrane fusion. As a proof-of-principle, we investigated alkyne-functionalized α-(1-(cholesteryloxy)ethoxy)-ω-hydro-PEG$_{46}$ (Ch-acetal-PEG$_{46}$-CH$_2$-C≡CH) in liposome formulations with respect to its shedding properties close to *in vivo* conditions. To this end, a fluorescent dye (Atto 488 azide) was attached to the polymer after liposome preparation *via* click-chemistry and acetal cleavage was studied *via* fluorescent spectroscopy (schematic representation Fig. 8). The crucial point is the protonation of the acetal groups that are located near the phospholipid membrane. As discussed below, it could be demonstrated that acetal-cleavage takes place, although the PEG layer may impede cleavage, slowing down acetal degradation.

Alkyne-containing amphiphiles were incorporated into liposomes in a molar fraction of 5 mol%. Liposomes were prepared *via* dual centrifugation, resulting in *z*-average hydrodynamic radii (±standard deviation (SD) of 3 measurements) of 170 ± 2.8 nm ($\mu_2/\Gamma^2 = 0.22$) and 154 ± 2.2 nm ($\mu_2/\Gamma^2 = 0.10$)

for amphiphiles with and without acetal groups, respectively. Low values for μ_2/Γ^2 indicated narrow size distributions as obtained from cumulant analysis of DLS data.

After functionalization of the terminal alkyne group with Atto 488 azide, fluorescent liposomes enabled the observation of the acidic shedding. It turned out that after dilution in PBS and during ongoing equilibration the fluorescence emission decreased to a certain value. This observation is believed to be due to changes in the microenvironment of the fluorophores, *e.g.*, during the partial transition from vesicles to micelles. The cleavage process was then observed after acidification, leading to a strong increase of fluorescence emission intensity, as shown in Fig. 9.

As expected, a low pH value of 2 led to a fast cleavage within several minutes and therefore high fluorescence emission, while the liposome system without cleavable amphiphiles showed no substantial increase (red data points).


Fig. 9 Fluorescence emission increases during acidic cleavage of acetal-containing amphiphiles (Ch-acetal-PEG$_{46}$-alkyne, black). Amphiphiles without acetal groups (Ch-PEG$_{41}$-alkyne, red) are stable at low pH.


Fig. 8 Schematic representation of the liposome functionalization and subsequent acidic cleavage of the PEG-coating.

However, higher pH values provided degradation within hours (pH 3) or even days (pH 5.5). The increase in fluorescence intensity can be explained by both less thermal relaxation of fluorophores due to surface-related interactions and a potentially lower inner filter effect. While the complex microenvironment within liposomes led to rather qualitative results, the kinetics of the cleavage were in good agreement with earlier measurements.[18] Although the cleavage at pH 5.5 was slow, it demonstrates a potential mechanism to shed the liposomal coating in lysosomal compartments. Therefore, the incorporation of acid-labile groups might enable both the elimination of polymeric moieties and the interaction between liposomal and cellular membranes.

Conclusion

In the present study, we showed the incorporation of multiple cleavable groups by combining the epoxide inimer GEGE and glycidol in the oxyanionic ring-opening polymerization with cholesterol as the initiator. Random or block copolymers (Ch-P(GEGE$_x$-co-G$_y$) or Ch-P(GEGE$_x$-b-G$_y$)) were synthesized with narrow molecular weight distributions, and the degradation of a block copolymer was investigated by SEC at pH = 2. Furthermore, hyperbranched polyglycerol with a single acetal moiety was introduced using glycol-1-(cholesteryloxy) ethylether as an initiator for the polymerization of AGE, subsequent thiol–ene coupling of 2-mercaptoethanol and polymerization of glycidol. To the best of our knowledge, this represents the first synthesis of acetal-containing hyperbranched lipids for liposome preparations. The polymers obtained are promising with respect to the combination of the following properties: (i) steric stabilization of liposomes, (ii) multifunctionality, (iii) acidic degradability, and (iv) biocompatibility. Degradability in liposome formulations was proven by using the linear analogue (1-(cholesteryloxy)ethoxy)-ω-hydro-PEG$_{46}$-CH$_2$-C≡CH functionalized with a fluorescent label (Atto 488 azide) at pH between 7.4 and 2.0. A strong pH-dependence for the shedding process was observed. We believe that acid-labile lipids with a high number of functionalities and multiple cleavable groups mark a promising development step for polyether-based lipids for future biomedical applications.

Acknowledgements

References

1 S. Amselem, A. Gabizon and Y. Barenholz, *J. Pharm. Sci.*, 1990, **79**, 1045–1052.
2 R. Duncan and R. Gaspar, *Mol. Pharmaceutics*, 2011, **8**, 2101–2141.
3 B. S. Pattni, V. V. Chupin and V. P. Torchilin, *Chem. Rev.*, 2015, **115**, 10938–10966.
4 A. Sharma and U. S. Sharma, *Int. J. Pharm.*, 1997, **154**, 123–140.
5 M. C. Woodle, K. K. Matthay, M. S. Newman, J. E. Hidayat, L. R. Collins, C. Redemann, F. J. Martin and D. Papahadjopoulos, *Biochim. Biophys. Acta*, 1992, **1105**, 193–200.
6 V. P. Torchilin, *Nat. Rev. Drug Discovery*, 2005, **4**, 145–160.
7 G. Blume and G. Cevc, *Biochim. Biophys. Acta*, 1990, **1029**, 91–97.
8 M. L. Immordino, F. Dosio and L. Cattel, *Int. J. Nanomed.*, 2006, **1**, 297–315.
9 R. L. Hong, C. J. Huang, Y. L. Tseng, V. F. Pang, S. T. Chen, J. J. Liu and F. H. Chang, *Clin. Cancer Res.*, 1999, **5**, 3645–3652.
10 Z. Amoozgar and Y. Yeo, *WIREs Nanomed. Nanobiotechnol.*, 2012, **4**, 219–233.
11 H. Maeda, J. Wu, T. Sawa, Y. Matsumura and K. Hori, *J. Controlled Release*, 2000, **65**, 271–284.
12 I. Mellman, R. Fuchs and A. Helenius, *Annu. Rev. Biochem.*, 1986, **55**, 663–700.
13 T. L. Andresen, S. S. Jensen and K. Jørgensen, *Prog. Lipid Res.*, 2005, **44**, 68–97.
14 A. de Milito and S. Fais, *Future Oncol.*, 2005, **1**, 779–786.
15 A. Asokan and M. J. Cho, *J. Pharm. Sci.*, 2002, **91**, 903–913.
16 E. Yuba, C. Kojima, A. Harada, T. S. Watarai and K. Kono, *Biomaterials*, 2010, **31**, 943–951.
17 K. Remaut, B. Lucas, K. Braeckmans, J. Demeester and S. C. de Smedt, *J. Controlled Release*, 2007, **117**, 256–266.
18 C. Dingels, S. S. Müller, T. Steinbach, C. Tonhauser and H. Frey, *Biomacromolecules*, 2013, **14**, 448–459.
19 E. R. Gillies, A. P. Goodwin and J. M. J. Fréchet, *Bioconjugate Chem.*, 2004, **15**, 1254–1263.
20 J. Shin, P. Shum and D. H. Thompson, *J. Controlled Release*, 2003, **91**, 187–200.
21 J. A. Boomer, M. M. Qualls, H. D. Inerowicz, R. H. Haynes, V. S. Patri, J.-M. Kim and D. H. Thompson, *Bioconjugate Chem.*, 2009, **20**, 47–59.
22 J. Shin, P. Shum, J. Grey, S.-I. Fujiwara, G. S. Malhotra, A. González-Bonet, S.-H. Hyun, E. Moase, T. M. Allen and D. H. Thompson, *Mol. Pharmaceutics*, 2012, **9**, 3266–3276.
23 X. Guo and F. C. Szoka, *Bioconjugate Chem.*, 2001, **12**, 291–300.
24 C. Masson, M. Garinot, N. Mignet, B. Wetzer, P. Mailhe, D. Scherman and M. Bessodes, *J. Controlled Release*, 2004, **99**, 423–434.
25 X. Guo, J. Andrew MacKay and F. C. Szoka Jr., *Biophys. J.*, 2003, **84**, 1784–1795.

26 R. M. Sawant, J. P. Hurley, S. Salmaso, A. Kale, E. Tolcheva, T. S. Levchenko and V. P. Torchilin, *Bioconjugate Chem.*, 2006, **17**, 943–949.

27 A. A. Kale and V. P. Torchilin, *Bioconjugate Chem.*, 2007, **18**, 363–370.

28 D. Chen, X. Jiang, Y. Huang, C. Zhang and Q. Ping, *J. Bioact. Compat. Polym.*, 2010, **25**, 527–542.

29 H. Xu, Y. Deng, D. Chen, W. Hong, Y. Lu and X. Dong, *J. Controlled Release*, 2008, **130**, 238–245.

30 C. Clawson, L. Ton, S. Aryal, V. Fu, S. Esener and L. Zhang, *Langmuir*, 2011, **27**, 10556–10561.

31 T. M. Allen and E. H. Moase, *Adv. Drug Delivery Rev.*, 1996, **21**, 117–133.

32 A. M. Hofmann, F. Wurm, E. Hühn, T. Nawroth, P. Langguth and H. Frey, *Biomacromolecules*, 2010, **11**, 568–574.

33 A. M. Hofmann, F. Wurm and H. Frey, *Macromolecules*, 2011, **44**, 4648–4657.

34 S. S. Müller, C. Dingels, A. M. Hofmann and H. Frey, Tailored Polymer Architectures for Pharmaceutical and Biomedical Applications, *Am. Chem. Soc.*, 2013, **1135**, 11–25.

35 D. Wilms, S.-E. Stiriba and H. Frey, *Acc. Chem. Res.*, 2010, **43**, 129–141.

36 R. K. Kainthan, J. Janzen, E. Levin, D. V. Devine and D. E. Brooks, *Biomacromolecules*, 2006, **7**, 703–709.

37 M. Imran ul-haq, B. F. Lai, R. Chapanian and J. N. Kizhakkedathu, *Biomaterials*, 2012, **33**, 9135–9147.

38 R. K. Kainthan, S. R. Hester, E. Levin, D. V. Devine and D. E. Brooks, *Biomaterials*, 2007, **28**, 4581–4590.

39 C. Siegers, M. Biesalski and R. Haag, *Chem. – Eur. J.*, 2004, **10**, 2831–2838.

40 R. A. Shenoi, B. F. L. Lai and J. N. Kizhakkedathu, *Biomacromolecules*, 2012, **13**, 3018–3030.

41 R. A. Shenoi, J. K. Narayanannair, J. L. Hamilton, B. F. L. Lai, S. Horte, R. K. Kainthan, J. P. Varghese, K. G. Rajeev, M. Manoharan and J. N. Kizhakkedathu, *J. Am. Chem. Soc.*, 2012, **134**, 14945–14957.

42 R. A. Shenoi, B. F. Lai, M. Imran ul-haq, D. E. Brooks and J. N. Kizhakkedathu, *Biomaterials*, 2013, **34**, 6068–6081.

43 C. Tonhauser, C. Schüll, C. Dingels and H. Frey, *ACS Macro Lett.*, 2013, **1**, 1094–1097.

44 U. Massing, S. Cicko and V. Ziroli, *J. Controlled Release*, 2008, **125**, 16–24.

45 T. Fritz, M. Hirsch, F. C. Richter, S. S. Müller, A. M. Hofmann, K. A. Rusitzka, J. Markl, U. Massing, H. Frey and M. Helm, *Biomacromolecules*, 2014, **15**, 2440–2448.

46 A. O. Fitton, J. Hill, D. E. Jane and R. Millar, *Synthesis*, 1987, 1140–1142.

47 P. Geissler and A. Johnson, *J. Am. Oil Chem. Soc.*, 1990, **67**, 541–546.

48 A. Johnson and P. Geissler, *J. Am. Oil Chem. Soc.*, 1990, **67**, 123–131.

49 J. Pollerberg, *Fette, Seifen, Anstrichm.*, 1966, **68**, 561–562.

50 E. Santacesaria, M. Di Serio, R. Garaffa and G. Addino, *Ind. Eng. Chem. Res.*, 1992, **31**, 2413–2418.

51 A. Sunder, R. Hanselmann, H. Frey and R. Mülhaupt, *Macromolecules*, 1999, **32**, 4240–4246.

52 B. W. Greenland, S. Liu, G. Cavalli, E. Alpay and J. H. Steinke, *Polymer*, 2010, **51**, 2984–2992.

53 B. F. Lee, M. J. Kade, J. A. Chute, N. Gupta, L. M. Campos, G. H. Fredrickson, E. J. Kramer, N. A. Lynd and C. J. Hawker, *Polym. Chem.*, 2011, **49**, 4498–4504.

54 A. Alkan, A. Natalello, M. Wagner, H. Frey and F. R. Wurm, *Macromolecules*, 2014, **47**, 2242–2249.